Plasma YKL-40 : A BMI-Independent Marker of Type 2 Diabetes
YKL-40 is produced by macrophages, and plasma YKL-40 is elevated in patients with diseases characterized by inflammation. In the present study, YKL-40 was examined in relation to obesity, inflammation, and type 2 diabetes. Plasma YKL-40 and adipose tissue YKL-40 mRNA levels were investigated in 199...
Gespeichert in:
| Veröffentlicht in: | Diabetes (New York, N.Y.) N.Y.), 2008-11, Vol.57 (11), p.3078-3082 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3082 |
|---|---|
| container_issue | 11 |
| container_start_page | 3078 |
| container_title | Diabetes (New York, N.Y.) |
| container_volume | 57 |
| creator | NIELSEN, Anders R ERIKSTRUP, Christian JOHANSEN, Julia S FISCHER, Christian P PLOMGAARD, Peter KROGH-MADSEN, Rikke TAUDORF, Sarah LINDEGAARD, Birgitte PEDERSEN, Bente K |
| description | YKL-40 is produced by macrophages, and plasma YKL-40 is elevated in patients with diseases characterized by inflammation. In the present study, YKL-40 was examined in relation to obesity, inflammation, and type 2 diabetes.
Plasma YKL-40 and adipose tissue YKL-40 mRNA levels were investigated in 199 subjects who were divided into four groups depending on the presence or absence of type 2 diabetes and obesity. In addition, plasma YKL-40 was examined in healthy subjects during a hyperglycemic clamp, in which the plasma glucose level was kept at 15 mmol/l for 3 h, and during a hyperinsulinemic-euglycemic clamp.
Patients with type 2 diabetes had higher plasma YKL-40 (76.7 vs. 45.1 ng/ml, P = 0.0001) but not higher expression in adipose tissue YKL-40 mRNA (1.20 vs. 0.98, P = 0.2) compared with subjects with a normal glucose tolerance. Within the groups with normal glucose tolerance and type 2 diabetes, obesity subgroups showed no difference with respect to either plasma YKL-40 or adipose tissue YKL-40 mRNA levels. Multivariate regression analysis showed that plasma YKL-40 was associated with fasting plasma glucose (beta = 0.5, P = 0.0014) and plasma interleukin (IL)-6 (beta = 0.2, P = 0.0303). Plasma YKL-40 was not related to parameters of obesity. There were no changes in plasma YKL-40 in healthy subjects during either hyperglycemic or hyperinsulinemic-euglycemic clamps.
Plasma YKL-40 was identified as an obesity-independent marker of type 2 diabetes related to fasting plasma glucose and plasma IL-6 levels. |
| doi_str_mv | 10.2337/db08-0182 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2570404</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A188730688</galeid><sourcerecordid>A188730688</sourcerecordid><originalsourceid>FETCH-LOGICAL-g470t-80e1bf4285d8425d1659d7e939be06bcd83caf8099a484f54f818b3de14350d73</originalsourceid><addsrcrecordid>eNptkm2L1DAQx4Mo3nr6wi8gRVDwRc7JQ5upgrCuei7ucb44QV-FtJnW3vVhbVrxvr2RWw9XloEEJr_5zz-TMPZYwIlUyrz0BSAHgfIOW4hc5VxJ8_UuWwAIyYXJzRF7EMIlAGQx7rMjgVkKKsMFe_25daFzybdPG64heZUsk7dna77uPW0pLv2UnLnxisZkqJKL6y0lMnnXuIImCg_Zvcq1gR7t9mP25cP7i9VHvjk_Xa-WG15rAxNHIFFUWmLqUcvUiyzNvaHosyDIitKjKl2FkOdOo65SXaHAQnkSWqXgjTpmb250t3PRkS-jqdG1djs2nRuv7eAau3_SN99tPfy0MjWgQUeB5zuBcfgxU5hs14SS2tb1NMzBZrmRRmsVwaf_gZfDPPbxclaKTGOm8j92-A1Uu5Zs01dDbFrW1FPsPfRUNTG9FIhGQYYY-ZMDfAxPXVMeLHixVxCZiX5NtZtDsHi62Wf5IbYc2pZqsvEdVuf7_JN_Z3k7xL8_IgLPdoALpWur0fVlE245CSijWK5-A0NMvZk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>216486397</pqid></control><display><type>article</type><title>Plasma YKL-40 : A BMI-Independent Marker of Type 2 Diabetes</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>NIELSEN, Anders R ; ERIKSTRUP, Christian ; JOHANSEN, Julia S ; FISCHER, Christian P ; PLOMGAARD, Peter ; KROGH-MADSEN, Rikke ; TAUDORF, Sarah ; LINDEGAARD, Birgitte ; PEDERSEN, Bente K</creator><creatorcontrib>NIELSEN, Anders R ; ERIKSTRUP, Christian ; JOHANSEN, Julia S ; FISCHER, Christian P ; PLOMGAARD, Peter ; KROGH-MADSEN, Rikke ; TAUDORF, Sarah ; LINDEGAARD, Birgitte ; PEDERSEN, Bente K</creatorcontrib><description>YKL-40 is produced by macrophages, and plasma YKL-40 is elevated in patients with diseases characterized by inflammation. In the present study, YKL-40 was examined in relation to obesity, inflammation, and type 2 diabetes.
Plasma YKL-40 and adipose tissue YKL-40 mRNA levels were investigated in 199 subjects who were divided into four groups depending on the presence or absence of type 2 diabetes and obesity. In addition, plasma YKL-40 was examined in healthy subjects during a hyperglycemic clamp, in which the plasma glucose level was kept at 15 mmol/l for 3 h, and during a hyperinsulinemic-euglycemic clamp.
Patients with type 2 diabetes had higher plasma YKL-40 (76.7 vs. 45.1 ng/ml, P = 0.0001) but not higher expression in adipose tissue YKL-40 mRNA (1.20 vs. 0.98, P = 0.2) compared with subjects with a normal glucose tolerance. Within the groups with normal glucose tolerance and type 2 diabetes, obesity subgroups showed no difference with respect to either plasma YKL-40 or adipose tissue YKL-40 mRNA levels. Multivariate regression analysis showed that plasma YKL-40 was associated with fasting plasma glucose (beta = 0.5, P = 0.0014) and plasma interleukin (IL)-6 (beta = 0.2, P = 0.0303). Plasma YKL-40 was not related to parameters of obesity. There were no changes in plasma YKL-40 in healthy subjects during either hyperglycemic or hyperinsulinemic-euglycemic clamps.
Plasma YKL-40 was identified as an obesity-independent marker of type 2 diabetes related to fasting plasma glucose and plasma IL-6 levels.</description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/db08-0182</identifier><identifier>PMID: 18650368</identifier><identifier>CODEN: DIAEAZ</identifier><language>eng</language><publisher>Alexandria, VA: American Diabetes Association</publisher><subject>Adipokines ; Adipose Tissue - metabolism ; Adult ; Antigens, CD - genetics ; Antigens, Differentiation, Myelomonocytic - genetics ; Biological and medical sciences ; Biological markers ; Biomarkers - blood ; Biopsy ; Blood Glucose - metabolism ; Body fat ; Body Mass Index ; Case-Control Studies ; Chitinase ; Chitinase-3-Like Protein 1 ; Cross-Sectional Studies ; Cytokines ; Diabetes ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - diagnosis ; Diabetes Mellitus, Type 2 - genetics ; Diabetes. Impaired glucose tolerance ; Diagnosis ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Enzymes ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Female ; Glucose ; Glucose Clamp Technique ; Glycoproteins - blood ; Glycoproteins - genetics ; Humans ; Inflammation ; Insulin resistance ; Kinases ; Lectins ; Male ; Medical sciences ; Middle Aged ; Obesity ; Pathophysiology ; Plasma ; Regression Analysis ; Research design ; Reverse Transcriptase Polymerase Chain Reaction ; RNA, Messenger - genetics ; RNA, Messenger - metabolism ; Tumor necrosis factor-TNF ; Type 2 diabetes</subject><ispartof>Diabetes (New York, N.Y.), 2008-11, Vol.57 (11), p.3078-3082</ispartof><rights>2009 INIST-CNRS</rights><rights>COPYRIGHT 2008 American Diabetes Association</rights><rights>Copyright American Diabetes Association Nov 2008</rights><rights>Copyright © 2008, American Diabetes Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2570404/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2570404/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20828879$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18650368$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>NIELSEN, Anders R</creatorcontrib><creatorcontrib>ERIKSTRUP, Christian</creatorcontrib><creatorcontrib>JOHANSEN, Julia S</creatorcontrib><creatorcontrib>FISCHER, Christian P</creatorcontrib><creatorcontrib>PLOMGAARD, Peter</creatorcontrib><creatorcontrib>KROGH-MADSEN, Rikke</creatorcontrib><creatorcontrib>TAUDORF, Sarah</creatorcontrib><creatorcontrib>LINDEGAARD, Birgitte</creatorcontrib><creatorcontrib>PEDERSEN, Bente K</creatorcontrib><title>Plasma YKL-40 : A BMI-Independent Marker of Type 2 Diabetes</title><title>Diabetes (New York, N.Y.)</title><addtitle>Diabetes</addtitle><description>YKL-40 is produced by macrophages, and plasma YKL-40 is elevated in patients with diseases characterized by inflammation. In the present study, YKL-40 was examined in relation to obesity, inflammation, and type 2 diabetes.
Plasma YKL-40 and adipose tissue YKL-40 mRNA levels were investigated in 199 subjects who were divided into four groups depending on the presence or absence of type 2 diabetes and obesity. In addition, plasma YKL-40 was examined in healthy subjects during a hyperglycemic clamp, in which the plasma glucose level was kept at 15 mmol/l for 3 h, and during a hyperinsulinemic-euglycemic clamp.
Patients with type 2 diabetes had higher plasma YKL-40 (76.7 vs. 45.1 ng/ml, P = 0.0001) but not higher expression in adipose tissue YKL-40 mRNA (1.20 vs. 0.98, P = 0.2) compared with subjects with a normal glucose tolerance. Within the groups with normal glucose tolerance and type 2 diabetes, obesity subgroups showed no difference with respect to either plasma YKL-40 or adipose tissue YKL-40 mRNA levels. Multivariate regression analysis showed that plasma YKL-40 was associated with fasting plasma glucose (beta = 0.5, P = 0.0014) and plasma interleukin (IL)-6 (beta = 0.2, P = 0.0303). Plasma YKL-40 was not related to parameters of obesity. There were no changes in plasma YKL-40 in healthy subjects during either hyperglycemic or hyperinsulinemic-euglycemic clamps.
Plasma YKL-40 was identified as an obesity-independent marker of type 2 diabetes related to fasting plasma glucose and plasma IL-6 levels.</description><subject>Adipokines</subject><subject>Adipose Tissue - metabolism</subject><subject>Adult</subject><subject>Antigens, CD - genetics</subject><subject>Antigens, Differentiation, Myelomonocytic - genetics</subject><subject>Biological and medical sciences</subject><subject>Biological markers</subject><subject>Biomarkers - blood</subject><subject>Biopsy</subject><subject>Blood Glucose - metabolism</subject><subject>Body fat</subject><subject>Body Mass Index</subject><subject>Case-Control Studies</subject><subject>Chitinase</subject><subject>Chitinase-3-Like Protein 1</subject><subject>Cross-Sectional Studies</subject><subject>Cytokines</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - diagnosis</subject><subject>Diabetes Mellitus, Type 2 - genetics</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Diagnosis</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Enzymes</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Female</subject><subject>Glucose</subject><subject>Glucose Clamp Technique</subject><subject>Glycoproteins - blood</subject><subject>Glycoproteins - genetics</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Insulin resistance</subject><subject>Kinases</subject><subject>Lectins</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Obesity</subject><subject>Pathophysiology</subject><subject>Plasma</subject><subject>Regression Analysis</subject><subject>Research design</subject><subject>Reverse Transcriptase Polymerase Chain Reaction</subject><subject>RNA, Messenger - genetics</subject><subject>RNA, Messenger - metabolism</subject><subject>Tumor necrosis factor-TNF</subject><subject>Type 2 diabetes</subject><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkm2L1DAQx4Mo3nr6wi8gRVDwRc7JQ5upgrCuei7ucb44QV-FtJnW3vVhbVrxvr2RWw9XloEEJr_5zz-TMPZYwIlUyrz0BSAHgfIOW4hc5VxJ8_UuWwAIyYXJzRF7EMIlAGQx7rMjgVkKKsMFe_25daFzybdPG64heZUsk7dna77uPW0pLv2UnLnxisZkqJKL6y0lMnnXuIImCg_Zvcq1gR7t9mP25cP7i9VHvjk_Xa-WG15rAxNHIFFUWmLqUcvUiyzNvaHosyDIitKjKl2FkOdOo65SXaHAQnkSWqXgjTpmb250t3PRkS-jqdG1djs2nRuv7eAau3_SN99tPfy0MjWgQUeB5zuBcfgxU5hs14SS2tb1NMzBZrmRRmsVwaf_gZfDPPbxclaKTGOm8j92-A1Uu5Zs01dDbFrW1FPsPfRUNTG9FIhGQYYY-ZMDfAxPXVMeLHixVxCZiX5NtZtDsHi62Wf5IbYc2pZqsvEdVuf7_JN_Z3k7xL8_IgLPdoALpWur0fVlE245CSijWK5-A0NMvZk</recordid><startdate>20081101</startdate><enddate>20081101</enddate><creator>NIELSEN, Anders R</creator><creator>ERIKSTRUP, Christian</creator><creator>JOHANSEN, Julia S</creator><creator>FISCHER, Christian P</creator><creator>PLOMGAARD, Peter</creator><creator>KROGH-MADSEN, Rikke</creator><creator>TAUDORF, Sarah</creator><creator>LINDEGAARD, Birgitte</creator><creator>PEDERSEN, Bente K</creator><general>American Diabetes Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>8GL</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20081101</creationdate><title>Plasma YKL-40 : A BMI-Independent Marker of Type 2 Diabetes</title><author>NIELSEN, Anders R ; ERIKSTRUP, Christian ; JOHANSEN, Julia S ; FISCHER, Christian P ; PLOMGAARD, Peter ; KROGH-MADSEN, Rikke ; TAUDORF, Sarah ; LINDEGAARD, Birgitte ; PEDERSEN, Bente K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g470t-80e1bf4285d8425d1659d7e939be06bcd83caf8099a484f54f818b3de14350d73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adipokines</topic><topic>Adipose Tissue - metabolism</topic><topic>Adult</topic><topic>Antigens, CD - genetics</topic><topic>Antigens, Differentiation, Myelomonocytic - genetics</topic><topic>Biological and medical sciences</topic><topic>Biological markers</topic><topic>Biomarkers - blood</topic><topic>Biopsy</topic><topic>Blood Glucose - metabolism</topic><topic>Body fat</topic><topic>Body Mass Index</topic><topic>Case-Control Studies</topic><topic>Chitinase</topic><topic>Chitinase-3-Like Protein 1</topic><topic>Cross-Sectional Studies</topic><topic>Cytokines</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - diagnosis</topic><topic>Diabetes Mellitus, Type 2 - genetics</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Diagnosis</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Enzymes</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Female</topic><topic>Glucose</topic><topic>Glucose Clamp Technique</topic><topic>Glycoproteins - blood</topic><topic>Glycoproteins - genetics</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Insulin resistance</topic><topic>Kinases</topic><topic>Lectins</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Obesity</topic><topic>Pathophysiology</topic><topic>Plasma</topic><topic>Regression Analysis</topic><topic>Research design</topic><topic>Reverse Transcriptase Polymerase Chain Reaction</topic><topic>RNA, Messenger - genetics</topic><topic>RNA, Messenger - metabolism</topic><topic>Tumor necrosis factor-TNF</topic><topic>Type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>NIELSEN, Anders R</creatorcontrib><creatorcontrib>ERIKSTRUP, Christian</creatorcontrib><creatorcontrib>JOHANSEN, Julia S</creatorcontrib><creatorcontrib>FISCHER, Christian P</creatorcontrib><creatorcontrib>PLOMGAARD, Peter</creatorcontrib><creatorcontrib>KROGH-MADSEN, Rikke</creatorcontrib><creatorcontrib>TAUDORF, Sarah</creatorcontrib><creatorcontrib>LINDEGAARD, Birgitte</creatorcontrib><creatorcontrib>PEDERSEN, Bente K</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Gale In Context: High School</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>NIELSEN, Anders R</au><au>ERIKSTRUP, Christian</au><au>JOHANSEN, Julia S</au><au>FISCHER, Christian P</au><au>PLOMGAARD, Peter</au><au>KROGH-MADSEN, Rikke</au><au>TAUDORF, Sarah</au><au>LINDEGAARD, Birgitte</au><au>PEDERSEN, Bente K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plasma YKL-40 : A BMI-Independent Marker of Type 2 Diabetes</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><addtitle>Diabetes</addtitle><date>2008-11-01</date><risdate>2008</risdate><volume>57</volume><issue>11</issue><spage>3078</spage><epage>3082</epage><pages>3078-3082</pages><issn>0012-1797</issn><eissn>1939-327X</eissn><coden>DIAEAZ</coden><abstract>YKL-40 is produced by macrophages, and plasma YKL-40 is elevated in patients with diseases characterized by inflammation. In the present study, YKL-40 was examined in relation to obesity, inflammation, and type 2 diabetes.
Plasma YKL-40 and adipose tissue YKL-40 mRNA levels were investigated in 199 subjects who were divided into four groups depending on the presence or absence of type 2 diabetes and obesity. In addition, plasma YKL-40 was examined in healthy subjects during a hyperglycemic clamp, in which the plasma glucose level was kept at 15 mmol/l for 3 h, and during a hyperinsulinemic-euglycemic clamp.
Patients with type 2 diabetes had higher plasma YKL-40 (76.7 vs. 45.1 ng/ml, P = 0.0001) but not higher expression in adipose tissue YKL-40 mRNA (1.20 vs. 0.98, P = 0.2) compared with subjects with a normal glucose tolerance. Within the groups with normal glucose tolerance and type 2 diabetes, obesity subgroups showed no difference with respect to either plasma YKL-40 or adipose tissue YKL-40 mRNA levels. Multivariate regression analysis showed that plasma YKL-40 was associated with fasting plasma glucose (beta = 0.5, P = 0.0014) and plasma interleukin (IL)-6 (beta = 0.2, P = 0.0303). Plasma YKL-40 was not related to parameters of obesity. There were no changes in plasma YKL-40 in healthy subjects during either hyperglycemic or hyperinsulinemic-euglycemic clamps.
Plasma YKL-40 was identified as an obesity-independent marker of type 2 diabetes related to fasting plasma glucose and plasma IL-6 levels.</abstract><cop>Alexandria, VA</cop><pub>American Diabetes Association</pub><pmid>18650368</pmid><doi>10.2337/db08-0182</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-1797 |
| ispartof | Diabetes (New York, N.Y.), 2008-11, Vol.57 (11), p.3078-3082 |
| issn | 0012-1797 1939-327X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2570404 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Adipokines Adipose Tissue - metabolism Adult Antigens, CD - genetics Antigens, Differentiation, Myelomonocytic - genetics Biological and medical sciences Biological markers Biomarkers - blood Biopsy Blood Glucose - metabolism Body fat Body Mass Index Case-Control Studies Chitinase Chitinase-3-Like Protein 1 Cross-Sectional Studies Cytokines Diabetes Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - genetics Diabetes. Impaired glucose tolerance Diagnosis Endocrine pancreas. Apud cells (diseases) Endocrinopathies Enzymes Etiopathogenesis. Screening. Investigations. Target tissue resistance Female Glucose Glucose Clamp Technique Glycoproteins - blood Glycoproteins - genetics Humans Inflammation Insulin resistance Kinases Lectins Male Medical sciences Middle Aged Obesity Pathophysiology Plasma Regression Analysis Research design Reverse Transcriptase Polymerase Chain Reaction RNA, Messenger - genetics RNA, Messenger - metabolism Tumor necrosis factor-TNF Type 2 diabetes |
| title | Plasma YKL-40 : A BMI-Independent Marker of Type 2 Diabetes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T00%3A14%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plasma%20YKL-40%20:%20A%20BMI-Independent%20Marker%20of%20Type%202%20Diabetes&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=NIELSEN,%20Anders%20R&rft.date=2008-11-01&rft.volume=57&rft.issue=11&rft.spage=3078&rft.epage=3082&rft.pages=3078-3082&rft.issn=0012-1797&rft.eissn=1939-327X&rft.coden=DIAEAZ&rft_id=info:doi/10.2337/db08-0182&rft_dat=%3Cgale_pubme%3EA188730688%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=216486397&rft_id=info:pmid/18650368&rft_galeid=A188730688&rfr_iscdi=true |